NCT00303563View on ClinicalTrials.gov

A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Rheumatoid Arthritis
Interventions
DRUG

P38 Inhibitor (4)

50mg po qd

DRUG

P38 Inhibitor (4)

150mg po qd

DRUG

P38 Inhibitor (4)

300mg po qd

DRUG

Placebo

po qd

Trial Locations (61)

114

Tapei

333

Taoyuan District

1619

Johannesburg

9301

Bloemfontein

11000

Belgrade

11407

Jerez de la Frontera

15006

A Coruña

16132

Genova

17604

Lancaster

17822

Danville

18014

Granada

21000

Split

25123

Brescia

27100

Pavia

28012

Belmont

28040

Madrid

29407

Charleston

29609

Brest

33006

Oviedo

34295

Montpellier

36207

Anniston

37203

Nashville

37909

Knoxville

38104

Memphis

40292

Louisville

41013

Seville

44340

Guadalajara

44620

Guadalajara

46601

South Bend

51000

Rijeka

60053

Morton Grove

67207

Wichita

70115

New Orleans

75231

Dallas

75679

Paris

76031

Rouen

79106

Amarillo

85251

Scottsdale

85704

Tucson

85712

Tucson

91106

Corbeil-Essonnes

92025

Escondido

92357

Loma Linda

97701

Bend

500366

Brasov

06905

Stamford

T5H 3V9

Edmonton

B3H 2Y9

Halifax

K2G 6E2

Ottawa

M5T 2S8

Toronto

370 01

České Budějovice

128 50

Prague

411 55

Terezín

760 01

Zlín

00161

Roma

06700

Miexico City

020125

Bucharest

0002

Pretoria

08035

Barcelona

07007

Palma de Mallorca

00833

Kaohsiung City

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00303563 - A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter